PharmaCyte Biotech Statistics
Total Valuation
PMCB has a market cap or net worth of $17.86 million. The enterprise value is -$43.60 million.
| Market Cap | 17.86M |
| Enterprise Value | -43.60M |
Important Dates
The last earnings date was Monday, March 18, 2024, after market close.
| Earnings Date | Mar 18, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PMCB has 8.46 million shares outstanding. The number of shares has decreased by -54.69% in one year.
| Shares Outstanding | 8.46M |
| Shares Change (YoY) | -54.69% |
| Shares Change (QoQ) | -1.80% |
| Owned by Insiders (%) | 8.12% |
| Owned by Institutions (%) | 15.05% |
| Float | 8.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.56 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.16, with zero debt.
| Current Ratio | 8.16 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.10% and return on invested capital (ROIC) is -19.47%.
| Return on Equity (ROE) | -25.10% |
| Return on Assets (ROA) | -15.20% |
| Return on Capital (ROIC) | -19.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.75M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.10% in the last 52 weeks. The beta is -0.16, so PMCB's price volatility has been lower than the market average.
| Beta (1Y) | -0.16 |
| 52-Week Price Change | -29.10% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 2.28 |
| Relative Strength Index (RSI) | 43.72 |
| Average Volume (30 Days) | 25,650 |
Short Selling Information
The latest short interest is 18,225, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 18,225 |
| Short Previous Month | 45,733 |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.23% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.11M |
| Pretax Income | -1.14M |
| Net Income | -11.51M |
| EBITDA | -1.14M |
| EBIT | -1.14M |
| Earnings Per Share (EPS) | -$1.20 |
Balance Sheet
The company has $61.21 million in cash and no debt, giving a net cash position of $61.21 million or $7.23 per share.
| Cash & Cash Equivalents | 61.21M |
| Total Debt | n/a |
| Net Cash | 61.21M |
| Net Cash Per Share | $7.23 |
| Equity / Book Value | 31.37M |
| Book Value Per Share | 3.71 |
| Working Capital | 53.97M |
Cash Flow
| Operating Cash Flow | -2.11M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.11M |
| FCF Per Share | -$0.25 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PMCB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 54.69% |
| Shareholder Yield | 54.69% |
| Earnings Yield | -65.36% |
| FCF Yield | -11.97% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 12, 2021. It was a reverse split with a ratio of 1:1550.
| Last Split Date | Jul 12, 2021 |
| Split Type | Reverse |
| Split Ratio | 1:1550 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |